Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: An effective strategy for the implementation of beta-blockade in heart failure

Italian Heart Journal

Volumn 5, Issue 6, 2004, Pages 441-449

  Tarantini, Luigi ^a   Cioffi, Giovanni ^b   Opasich, Cristina ^c   Di Lenarda, Andrea ^d   Pulignano, Giovanni ^e   Del Sindaco, Donatella ^f   De Feo, Stefania ^c   Stefenelli, Carlo ^b   Russo, Paola ^a   Catania, Giuseppe ^a  

^a SAN MARTINO HOSPITAL   (Italy)

^b Villa Bianca Hospital   (Italy)

^c IRCCS   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f INRCA   (Italy)

Author keywords

Aging; Beta blockers; Congestive heart failure; Management in cardiology; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE;

AGED; ARTICLE; CHI SQUARE DISTRIBUTION; CONGESTIVE HEART FAILURE; FEASIBILITY STUDY; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; PROSPECTIVE STUDY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARBAZOLES; CHI-SQUARE DISTRIBUTION; FEASIBILITY STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; PATIENT DISCHARGE; PROPANOLAMINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 6944228062     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001; 104: 2996-3007.
2. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail 1999; 5: 357-82.
3. Fonarow GC. Quality indicators for the management of heart failure in vulnerable elders. Ann Intern Med 2001; 135: 694-702.
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
5. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
7. Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. US Carvedilol Heart Failure Study Group. J Am Coll Cardiol 2001; 37: 1692-9.
8. Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in heart failure. Am J Med 2001; 110 (Suppl 7A): 74S-80S.
9. Ansari M, Alexander M, Tutar A, Bello D, Massie BM. Cardiology participation improves outcomes in patients with new onset heart failure in the outpatient setting. J Am Coll Cardiol 2003; 41: 62-8.
10. Komajda M, Follath F, Swedberg K, et al, for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-74.
11. Maggioni AP, Sinagra G, Opasich C, et al, for the Beta blockers in patients with congestive heart failure: guided use in clinical practice Investigators. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart 2003; 89: 299-305.
12. Pulignano G, Del Sindaco D, Tavazzi L, et al, for the IN-CHF Investigators. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 2002; 143: 45-55.
13. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 360: 1631-9.
14. Gattis WA, O'Connor CM, Gheorghiade M. The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. Rev Cardiovasc Med 2002; 3 (Suppl 3): S48-S54.
15. Lien CT, Gillespie ND, Struthers AD, McMurdo ME. Heart failure in frail elderly patients: diagnostic difficulties, comorbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail 2002; 4: 91-8.
16. Baxter AJ, Spensley A, Hildreth A, Karimova G, O'Connel JE, Gray CS. Beta-blockers in older persons with heart failure: tolerability and impact on quality of life. Heart 2002; 88: 611-4.
17. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-9.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
19. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67.
20. Miyatake K, Izumi S, Okamoto M, et al. Semiquantitative grading of severity of mitral regurgitation by real time two-dimensional Doppler flow imaging technique. J Am Coll Cardiol 1986; 7: 82-8.
21. National Health Service Center for Reviews and Dissemination. Effective health care: getting evidence into practice. London, UK: Royal Society of Medicine Press, 1999: 1-16.
22. McDonald K, Ledwidge M. Heart failure management programs. Can we afford to ignore the inpatient phase of care? J Card Fail 2003; 4: 258-62.
23. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003; 326: 196-202.
24. Wolinsky FD, Smith DM, Stump TE, Overhage JM, Lubitz RM. The sequelae of hospitalization for congestive heart failure among older adults. J Am Geriatr Soc 1997; 45: 558-63.
25. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157: 99-104.
26. Krum H, Roecker EB, Mohacsi P, et al, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003; 289: 712-8.
27. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999; 33: 924-31.
28. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 2000; 356: 639-44.
29. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11 942 elderly patients with heart failure. Am J Med 2002; 113: 650-6.
30. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994; 89: 1632-42.
31. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94: 2807-16.
32. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II: the aging heart in health: links to heart disease. Circulation 2003; 107: 346-54.
33. Cioffi G, Stefenelli C. Tolerability and clinical effects of carvedilol in very elderly patients with heart failure due to left ventricular dysfunction. Ital Heart J 2001; 2: 1319-29.
34. Cioffi G, Stefenelli C, Tarantini L, Opasich C. Prevalence, predictors and prognostic implications of improvement in left ventricular systolic function and clinical status in patients >70 years of age with recently diagnosed systolic heart failure. Am J Cardiol 2003; 92: 166-72.
35. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 2000; 84: 615-9.
36. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21: 1290-5.